Editorial: The role of epigenetic modification in radiotherapy and immuno-oncology in cancer: from bench to clinical application

Hon-Yi Lin; Michael W Y Chan; Vivian W Y Lui; Peter J K Kuppen; Shih-Kai Hung

doi:10.3389/fonc.2023.1213513

Editorial: The role of epigenetic modification in radiotherapy and immuno-oncology in cancer: from bench to clinical application

Front Oncol. 2023 May 16:13:1213513. doi: 10.3389/fonc.2023.1213513. eCollection 2023.

Authors

Hon-Yi Lin^{1

2

3

4}, Michael W Y Chan⁴, Vivian W Y Lui⁵, Peter J K Kuppen⁶, Shih-Kai Hung^{1

2

3}

Affiliations

¹ Department of Radiation Oncology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-yi, Taiwan.
² Cancer Centre, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-yi, Taiwan.
³ School of Medicine, Tzu Chi University, Hualien, Taiwan.
⁴ Department of Biomedical Sciences, National Chung Cheng University, Chia-Yi, Taiwan.
⁵ Georgia Cancer Center and Department of Medicine, Medical College of Georgia, Augusta University, Augusta, GA, United States.
⁶ Department of Surgical Oncology, Leiden University Medical Centre, ZA, Leiden, Netherlands.

No abstract available

Keywords: cancer; epigenetic modification; immune-oncology (IO); immunotherapy; radiotherapy (RT).

Publication types

Editorial

Grants and funding

The present study was supported by the Ministry of Science and Technology, Taiwan (Grant Number, 106-2923-B-194-001-MY3), and the Buddhist Tzu Chi Medical Foundation (Grant Number, TCMMP105-09-02[-04], TCMMP106-02-02[-04], TCMF-A 111-10, TCMF-A 112-04, and DTCRD106[2]-E-18).